To sign up for our e-mail newsletter or print publications, fill out the information below and click Subscribe.
Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.
Michael J. Mauro, MD
Two-pronged attack on chemotherapy-resistant leukemia cells
An Early Look at Research From the 2016 ASCO Annual Meeting
Drug against breast cancer is also highly potent against a frequent form of leukaemia
Improving natural killer cancer therapy: Study